Up to date, in addition to three products launched commercially and one product under NDA review, Henlius has conducted over 20 clinical studies for 10 products and 8 combination therapies worldwide. 汉利康® (HLX01, rituximab injection), the first product of Henlius, has been approved by the NMPA as China’s first biosimilar in February 2019. The second product 汉曲优® (HLX02, trastuzumab injection, Zercepac® in the EU) was launched both in China and Europe in 2020, becoming the first Chinese mAb biosimilar entering both the EU and China market. It will bring more treatment options to patients with HER2 positive breast and gastric cancer worldwide. 汉达远® (HLX03, adalimumab injection) is the first China-developed adalimumab biosimilar that is manufactured in a China and Europe GMP certificated manufacturing site. HLX01 (rituximab injection) indicated for rheumatoid arthritis and HLX04 (bevacizumab injection) were accepted for New Drug Application (NDA) review by the NMPA.